Significados de relapse myeloma en inglés

Treatment options for patients with relapsed myeloma are a rapidly moving entity.

The role of ASCT as salvage therapy in relapsed myeloma remains unclear.

Bortezomib-associated peripheral neuropathy is manageable and reversible in most patients with relapsed myeloma.

In conclusion, bortezomib had substantial activity in relapsed myeloma patients; CR may be a surrogate marker for significant clinical benefit with bortezomib.

Methods: Retrospective review of patients treated salvage ASCT for relapsed myeloma at our centre from 1992 to 2011.

Background: Thalidomide, as a single agent, has been recently found to induce a clinical response in one third of refractory or relapsed myeloma patients.